Exciting news on experimental treatments! A new study on Type 1 diabetics showed that injecting the antibody anti-CD3 may help "stop this autoimmune disease in its tracks," according to JDRF executive VP for research Dr. Richard Insel.
Researchers at Necker Hospital in Paris apparently tested this "novel approach" on newly diagnosed Type 1 diabetics who still had some insulin function left. The results, published last week in the New England Journal of Medicine, were encouraging enough for the JDRF to plan future large-scale studies.
What they did this time was randomly divide 80 patients recently
diagnosed with Type 1 diabetes into two groups -- one getting the antibody treatment intravenously and the other getting a
placebo. The researchers recorded insulin doses and evaluated
American Diabetes Association Names New CEO
Non-profit leader Kevin L. Hagan named as new chief exec of national diabetes org after six-month search.
FDA Approves New Basal Insulin
Sanofi's Troujeo has 'flatter profile' of action that helps to avoid lows.
Daytona Win for Racecar Driver with Diabetes!
Type 1 driver Ryan Reed wins first NASCAR series race at Daytona on Feb. 21.
how well the patients' pancreatic cells produced insulin at the
beginning of the study and also at six, 12, and 18 months following treatment.
What they found out was that within the 18 months, the placebo patients needed more insulin and had a decrease in the functioning of their insulin-producing cells, whereas the anti-body receivers had little change at all in their insulin needs or islet cell function. In other words, it looks like the drug may stop the attack on pancreatic cells!
BUT: there are safety concerns. Most who got the treatment had side effects including headaches, fever, joint aches, and rashes. These are supposedly temporary, but could increase risk of a blood disorder down the line.
AND: "Since the trial lasted for only 18 months, it is unclear if the treatment could 'wear off' after a certain period of time."
Yes, we know: Don't get too excited. But a fascinating development, nonetheless.